Cargando…
Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome
Autores principales: | Goyal, Amrita, Narayanan, Damodaran, Wong, Waihay, Laga, Alvaro C., Connell, Nathan T., Ritter, Susan Y., Cobos, Gabriela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980309/ https://www.ncbi.nlm.nih.gov/pubmed/35391910 http://dx.doi.org/10.1016/j.jdcr.2022.02.022 |
Ejemplares similares
-
Pulmonary manifestations in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome: a systematic review
por: Kouranloo, Koushan, et al.
Publicado: (2023) -
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome—clinical presentation of a newly described somatic, autoinflammatory syndrome
por: Alhomida, Faris, et al.
Publicado: (2021) -
Innovations in genomics for undiagnosed diseases: vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome
por: Stubbins, Ryan J., et al.
Publicado: (2022) -
A case of VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) with decreased oxidative stress levels after oral prednisone and tocilizumab treatment
por: Tozaki, Nagie, et al.
Publicado: (2022) -
VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder
por: Huang, Huijun, et al.
Publicado: (2021)